Trial Identification,NCT#,Phase,Cancer Type,Sponsor,Findings,Conclusions,Study Groups,Group Info,ORR,PFS,OS
Trial1-Info:gen-1728211025-CWXl7GqK7WmvNNhDBp5a,1,"Not specified, but likely Phase 2 or Phase 3 given the randomized controlled trial design",Breast Cancer (BC) in women undergoing anthracycline-based chemotherapy,Not specified,"The trial found that wearable device-based aerobic exercise during chemotherapy can improve physical and mental health in BC patients, including increased physical fitness, reduced anxiety and depression, improved sleep quality, and reduced cancer-related fatigue.",The trial concluded that wearable device-based aerobic exercise can be an effective adjunctive therapy to improve physical and mental health in BC patients undergoing chemotherapy.,Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211058-C2l63vl4Kb7iy7yUEDTi,1,Phase 3,"Metastatic Breast Cancer, specifically ER+ HER2- (estrogen receptor-positive, human epidermal growth factor receptor 2-negative)","Not provided (possibly Mansoura University, Egypt, but not explicitly stated)","The trial found that both ribociclib and palbociclib have similar clinical benefit rates (CBR), progression-free survival (PFS), and toxicity profiles when used in combination with fulvestrant as a second-line treatment for metastatic breast cancer.","The trial concluded that both ribociclib and palbociclib are effective and safe options for the treatment of metastatic breast cancer, with no significant differences in CBR, PFS, or toxicity profiles.",Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211087-5twBagcn77zKl9gWSM86,1,Not specified (pre-implementation analysis),"High-risk breast lesions that increase the risk of breast cancer, including atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS)",Not specified,"Providers were interested in the early inclusion of decision aids in their chemoprevention discussion workflow, and these aids may help overcome barriers to chemoprevention.",A multi-faceted intervention with a decision aid as one active component may be needed to improve informed choice about chemoprevention among women with high-risk breast lesions.,Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211144-EdV5Ad4u0qLCJlSS7qlC,1,"Protocol (This study is a randomized controlled trial protocol, but the phase is not explicitly stated)","Cancers that affect the central nervous system, including the brain and spinal cord",The sponsors are not explicitly stated in the provided text,"This study aims to investigate the effectiveness of the CCLIP in reducing medical fear in children with CNS cancers, but no results are reported in the provided text","No conclusions are reported in the provided text, as this is a study protocol",Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211173-GfeEPTUSIk95ItGOOWDb,1,Phase 3,Recurrent or metastatic cervical cancer.,"Regeneron Pharmaceuticals, Inc.",Cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first-line platinum-based chemotherapy.,The hazard ratio (HR) of 0.86 observed in Japanese patients suggests an emerging survival benefit despite a 4.6-month shorter median duration of follow-up versus the overall study population.,Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211199-tXGIJuPr5Gssh4BYgzaD,3,"Not explicitly stated, but based on the trial design, it appears to be a Phase 3 trial.",Invasive Breast Cancer,"Not explicitly stated, but funding was received from various pharmaceutical companies.","On-treatment biopsies can predict patients unlikely to achieve pathologic complete response (pCR) post-therapy, and changes in tumor-infiltrating lymphocytes (TILs) and Ki-67 expression were associated with pCR and disease-free survival (DFS).","On-treatment biopsies can facilitate therapy adjustments for triple-negative breast cancer (TNBC) or HER2-positive (HER2+) breast cancer, and may offer insights into therapy resistance mechanisms.",Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211234-0vKzwOZfjpSI594dagIq,1,"Not specified, assumed to be Phase 2 or 3 based on the data provided, but no clear indication of the phase.",The clinical trial focuses on breast cancer survivors with insomnia symptoms.,"Not specified, but grants were received from the Sleep Health and Wellness Center, the National Cancer Institute (NCI), the Maryland Department of Health, and the Centers for Disease Control and Prevention.",The trial found that a voice-activated cognitive behavioral therapy for insomnia (CBT-I) program improved insomnia symptoms among breast cancer survivors.,"The trial concluded that the CBT-I program was effective in improving insomnia symptoms among breast cancer survivors, and future studies may explore how this program can be scaled up and integrated into ambulatory care.",Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211255-1dcnU7MDBRNIZv7clxlg,1,"Not specified, but it is a randomized controlled trial, which is typically Phase 2 or Phase 3.","Not applicable, as this trial is not studying cancer.",Not specified,"The trial found that acellular dermal matrix (ADM) without basement membrane had similar surgical outcomes to ADM with basement membrane in immediate prepectoral breast reconstruction, and had a lower rate of seromas.","The trial concluded that ADM without basement membrane is safe and has mechanical properties of lower tensile strength and higher elasticity, making it suitable for implant-based breast reconstruction.",Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211311-QYeMn5d88VCbOxf01DmU,1,"Not specified, but it is a pilot trial, which is often a precursor to a larger Phase 2 or 3 trial.","The trial studied patients with breast, gastrointestinal, and multiple myeloma cancers who were undergoing neurotoxic chemotherapy.",Not specified,"The trial found that exercise during neurotoxic chemotherapy may attenuate chemotherapy-induced peripheral neurotoxicity (CIPN) symptoms and signs, and that changes in interoceptive brain circuitry may play a role in this effect.","The trial concluded that exercise during neurotoxic chemotherapy is feasible and may be beneficial for reducing CIPN symptoms and signs, and that future work should test for replication with larger samples.",Not specified,Not specified,Not specified,Not specified,Not specified
Trial1-Info:gen-1728211346-gCy8YRyg5uoQKhn6qMKm,1,Phase III,Not specified (only general breast cancer mentioned),Not explicitly stated (authors affiliated with various medical institutions and Evive Biotechnology Shanghai Ltd),The trial found that a single fixed dose of F-627 (efbemalenograstim alfa) was non-inferior to daily filgrastim in reducing neutropenia and its complications in patients with breast cancer receiving chemotherapy.,The conclusion was that a single fixed dose of 20mg of F-627 in each cycle was as safe and effective as a daily dose of filgrastim 5Î¼g/kg/d in reducing neutropenia and its complications in patients who received four cycles of EC.,Not specified,Not specified,Not specified,Not specified,Not specified
